儿童唐氏综合征的婴儿:潜在的机制驱动治疗考虑
Carl E Stafstrom1, Li-Rong Shao1
1Division of Pediatric Neurology, Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Children (Basel, Switzerland)
|January 8, 2025
概括
唐氏综合症 (DS) 增加了婴儿的风险,原因是大脑机制不清楚. 新的小鼠模型揭示了异常的大脑激发和抑制,为发育和潜在治疗提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 的研究研究.
背景情况:
- 在唐氏综合征 (DS) 中,婴儿是常见的,但潜在的机制仍然不清楚.
- 由激发-抑制不平衡驱动的神经元刺激性,是发作倾向的基础.
- 动物模型对于理解机制和开发治疗策略至关重要.
研究的目的:
- 审查唐氏综合征 (DS) 动物模型中的刺激性和抑制性功能障碍.
- 探索这些功能障碍在发作和婴儿发作的作用.
- 为过去的研究提供视角,并指导DS相关的婴儿的未来治疗开发.
主要方法:
- 对DS动物模型的现有文献的审查,包括Ts65Dn和TcMAC21小鼠.
- 对这些模型中检查神经元刺激性和抑制性的研究进行分析.
- 专注于对胺黄油酸 (GABA) 受体激动剂和电图活性的反应.
主要成果:
- 无论是 Ts65Dn 和 TcMAC21 两种小鼠模型,在 GBL 给药时都表现出类似婴儿的活性.
- 在DS模型中,证据表明异常的大脑刺激和持续的去极化GABA-A反应.
- 与Ts65Dn.n.相比,TcMAC21模型提供了更具遗传相关性的人类DS表征.
结论:
- 在DS模型中,刺激性和抑制性功能障碍与婴儿有关.
- 改进的动物模型,如TcMAC21,提高了对DS相关的理解.
- 对这些机制的进一步研究可能会导致针对唐氏综合征婴儿的向治疗.
相关概念视频
01:29Spasmolytic Agents: Chemical Classification
854
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
854
01:31Skeletal Muscle Relaxants: Therapeutic Uses
463
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
463
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
620
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
620
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
321
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
321
01:19Autism Spectrum Disorder
58
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
58
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
240
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
240